Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amgen says migraine...

    Amgen says migraine prevention drug meets main goal of study

    Written by savita thakur thakur Published On 2016-06-11T16:32:53+05:30  |  Updated On 11 Jun 2016 4:32 PM IST
    Amgen says migraine prevention drug meets main goal of study

    An experimental drug for prevention of chronic migraine headaches from Amgen Inc met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo, the company said on Wednesday.


    The biotech drug, erenumab, which is being co-developed with Swiss drugmaker Novartis, was tested at two doses in a 12-week, 667-patient Phase II study of subjects who were experiencing about 18 migraine days a month.


    Patients who received either the 70 milligram or 140 mg doses injected once monthly experienced a 6.6-day reduction in monthly migraine days, according to initial results. That compared with a 4.2-day reduction for those who received a placebo, a difference deemed to be statistically significant.


    Amgen expects to release more detailed data, including secondary goals such as reduction of at least 50 percent in monthly migraine days and change in cumulative monthly headache hours, at a later date.


    The company is also expecting data later this year from a late stage study of the medicine for patients who suffer from episodic migraines. Chronic was defined as having at least 15 headache days per month over 3 months, while 4 to 14 headache days per month was considered episodic.


    Between three and seven million Americans suffer from chronic migraines, which often involve nausea, vomiting and intense sensitivity to light and sound, in addition to incapacitating head pain.


    "Migraine is the sixth leading cause of disability worldwide," Sean Harper, Amgen's research chief, said in a statement.


    The safety of erenumab was similar to placebo, the company said. The most common side effects involved injection site pain and upper respiratory tract infections.


    Under the collaboration agreement with Novartis, Amgen holds the sales rights for the United States, Canada and Japan, while Novartis would sell the drug in Europe and the rest of the world if it wins regulatory approval.


    (Reporting by Bill Berkrot; Editing by Andrew Hay)





    AmgenAndrew HayBill BerkrotCollaborationMigraineNovartis
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok